Back to Resources
Market Highlights
- During Q3 2025, the ex-US biologics for GI market in Canada and Europe targeted mostly German healthcare professionals with digital direct mail pieces as the promotional channel.
- UCB highlighted its commitment to patient-inspired innovation through Cimzia’s “The Art of Innovation” campaign.
- AbbVie advertised Rinvoq’s status as “the first and only JAK inhibitor with 8 indications,” including UC and CD. Skyrizi was promoted as the first and only IL-23 p19 inhibitor approved for several indications, including CD, offering simplicity four times a year.
- Johnson and Johnson featured Simponi as “the most dispensed biologic DMARD by rheumatologists,” while Stelara advertised the 90 mg One-Press pen for SC maintenance and price competitiveness. Tremfya announced its approval for UC and the new IV formulation.
- Lilly announced Omvoh’s 42% price cut at biosimilar-level pricing and highlighted long-term efficacy with clinical studies, along with the Lilly app and the new Vohice platform. Familiar visual campaigns were observed.
- Pfizer promoted the S1P Saga series, Velsipity’s official reimbursement for UC, and the ELEVATE studies. The “Chaos and Calm” campaign was observed. In Canada, Xeljanz publicized the PfizerFlex Support Program.
Questions about this SnapShot or other markets?
U.S. MARKETS
Christine Alongi
alongi@dtwresearch.com
GLOBAL MARKETS
Robin Cefalo
cefalo@dtwresearch.com
SOCIAL MEDIA MARKETS
Andrew Carney
carney@dtwresearch.com